Abstract
Droloxifene, a new antiestrogen, has theoretical advantages over tamoxifen based on preclinical data. These include higher affinity to the estrogen receptor, higher antiestrogenic to estrogenic ratio, and more effective inhibition of cell growth and division in ER positive cell lines, as well as less toxicity, including reduced carcinogenicity in animal models. Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. A phase II study compared droloxifene in dosages of 20, 40, and 100 mg daily in postmenopausal women with metastatic, or inoperable recurrent, or primary locoregional breast cancer who had not received prior hormonal therapy. Of 369 patients randomized, 292 were eligible and 268 evaluable for response. Response rates (CR + PR) were 30% in the 20 mg group, 47% in the 40 mg group, and 44% in the 100 mg group (40 mg vs 20 mg, p = 0.02; 100 mg vs 20 mg, p = 0.04; pooled 40 + 100 mg vs 20 mg, p = 0.01). Median response duration also favoured the higher dosages (20 mg group = 12 months; 40 mg group = 15 months; 100 mg group = 18 months). When adjusted for prognostic factors, time to progression was significantly better for the 100 mg (p = 0.01) and the 40 mg (p = 0.02) group compared to the 20 mg group. Droloxifene increased SHBG and suppressed FSH at all dosages and suppressed LH at the 40 and 100 mg dosages. These hormonal effects increased with increasing dosage. Shortterm toxicity was generally mild, and similar to that seen with other antiestrogens. Droloxifene appears active and tolerable. It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.
Similar content being viewed by others
References
Roos WK, Oeze L, Löser R, Eppenberger U: Antiestrogen action of 3-hydroxy-tamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst 71: 55–59, 1983
Löser R, Seibel K, Roos W, Eppenberger U:In vivo andin vitro antiestrogenic action of 3-hydroxy-tamoxifen, tamoxifen, and 4-hydroxy-tamoxifen. Eur J Cancer Clin Oncol 21: 985–990, 1985
Kawamura I, Mizota T, Mukumoto S, Manda T, Masuda K, Nakamura T, Kubota H, Matsumoto S, Nishigaki F, Shimomura K: Antiestrogenic and antitumor effects of Droloxifene in experimental breast carcinoma. Arzneim Forsch/Drug Res 39 (8): 889–893, 1989
Dietel M, Löser R, Rohlke P, Jonat W, Niendorf A, Gerding D, Kohr A, Holzel F, Arps H: Effect of continuous versus intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1. J Cancer Res Clin Oncol 115 (1): 36–40, 1989
Eppenberger U, Wosikowski K, Küng W: Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 141: (Suppl 2): S5-S14, 1991
Hasmann M, Löser R, Seibel Ket al.: Cell cycle analyses of human breast cancer cells confirm superior growth inhibition of droloxifene versus tamoxifen. In: 3rd 1st International Symposium ‘Biology and Therapy of Breast Cancer’, Genoa, Italy, September 25-27, 1989
Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifene, and toremifene in MCF-7 cells. Am J Clin Oncol 14 (Suppl 2): S15-S20, 1991
Löser R: Effect of droloxifene on the growth of DMBA induced mammary tumors in rats. Klinge Pharma Report, September 1979
Löser R, Rattel B: Effect of droloxifene on human breast carcinomas grown in nude mice. Klinge Pharma Report, October 1987
Liehn HD: The toxicity of 3-hydroxy-tamoxifen and tamoxifen citrate: semichronic toxicity in rats on oral administration over four weeks. Klinge Pharma Toxicology Report No. 76, August 1983
Liehn HD: The toxicity of 3-hydroxy-tamoxifen citrate: semichronic toxicity in rats on oral administration over four weeks. Klinge Pharma Toxicology Report No. 77, September 1983
Liehn HD: The toxicity of 3-hydroxy-tamoxifen: chronic oral toxicity in rats over six months. Klinge Pharma Toxicology Report No. 81, October 1986
Rattel B: Droloxifene - on the chronic oral toxicity of 3-hydroxy-tamoxifen in rats over six months - plasma concentrations of 3-OH-tamoxifen and tamoxifen. Klinge Pharma Toxicology Report No. 81a, October 1987
Rattel B: Substance K21.060E citrate-reference tamoxifen citrate test No.81: chronic toxicity in the rat. Additional histological carcinogenicity study of liver lesions found in the tamoxifen high dose group D. Klinge Pharma Toxicology Report, 14, November 1986
Liehn HD: On the toxicology of 3-hydroxy-tamoxifen: chronic toxicity in marmosets by oral application over the test period of seven months. Klinge Pharma Toxicology Report No. 89, February 1985
Metzler M, Schiffmann D: Structural requirements for thein vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene - type antiestrogens. Am J Clin Oncol 14 (Suppl 2): S30-S35, 1991
Rattel B: Personal communication
Löser R, Seibel K, Liehn HD, Staab HJ: Pharmacology and toxicology of the antiestrogen droloxifene. Contrib Oncol 23: 64–72, 1986
Grill HJ, Pollow K: Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol 14 (Suppl 2): S21-S29, 1991
Lien EA, Solheim E, Leo OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49 (8): 2175–2183, 1989
Breitbach GP, Moous V, Bastert G, Kreienberg R, Muset MJ, Staab HJ: Droloxifene: Efficacy and endocrine effects in treatment of metastatic breast cancer. J Steroid Biochem 28: (Suppl), 1095, 1987
Stamm H, Roth R, Almendral A, Staab HJ, Heil M: Tolerance and efficacy of the antiestrogen droloxifene in patients with advanced breast cancer. J Steroid Biochem 28: (Suppl), 1085, 1987
Deschênes L (for the Droloxifene 002 International Study Group): Droloxifene, a new antiestrogen in advanced breast cancer. Am J Clin Oncol 14 (Suppl 2): S52-S55, 1991
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981
Possinger K, Wilmanns W: Prognosis-adapted treatment strategy in metastatic breast cancer. In Therapeutic Managementof Breast Cancer - Consensus Development in Cancer Therapy: 57-65, 1989
Buzdar A, Kau S, Hortobagyi G, Holmes F, Theriault R, Booser D, Krakoff I: A Phase I trial of Droloxifene in thirty patients with metastatic breast cancer. Proc Am Assoc Cancer Res 33: 260, 1992
Staab HJ, Pechan R: Dose escalation study: Tolerance of a new antiestrogen: Droloxifene. Klinge Pharma Final Report 0621: 4–85, May 1987
Delorme F: Droloxifene 200 mg and 300 mg once a day: a phase I safety study in patients with advanced breast cancer. Report CDC 0390, Rhone Poulenc Canada Inc
Dickson D: Tolerance and pharmacokinetics after single dose of Droloxifene (200, 300, 400, 500 mg) in postmenopausal patients with metastatic breast cancer. Report DRL 80-91, 1991
Amaya T: Results of Phase I study of Droloxifene (20, 40, 80, 160, 320 mg). Final report (English version), Fujisawa Ltd, Osaka, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rauschning, W., Pritchard, K.I. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Tr 31, 83–94 (1994). https://doi.org/10.1007/BF00689679
Issue Date:
DOI: https://doi.org/10.1007/BF00689679